LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Liquidia...
Covered in this story
Analyst targets on Liquidia Corp
- Wells Fargo: $28.6 → $30 by Oct 2027 · Equal Weight via Seeking Alpha
- H.C. Wainwright: $28.6 → $58 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LQDA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Liquidia Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.